Y-Biologics Inc. announced that it will receive up to KRW 30,000,000,000 in a round of funding on February 24, 2022. The transaction will include participation from twenty-five returning investors, including DAYLI Partners Co., Ltd., DS Asset Management Co., Ltd, Smilegate Investment, Inc., Korea Omega Investment Corp, Mirae Asset Securities Co., Ltd., Kolon Investment, Inc., HK inno.N Corporation, GI Innovation, Inc., and Genexine, Inc.